Prostate-specific membrane antigen-PET/CT may result in stage migration in prostate cancer: performances, quantitative analysis, and potential criticism in the clinical practice.

Autor: Alongi P; Nuclear Medicine Unit, Department of Radiological Sciences,  ., Messina M; Oncology Unit, Department of Surgery, A.R.N.A.S. Civico, Via Piazzale Leotta, Palermo and  ., Pepe A; Oncology Unit, Department of Surgery, A.R.N.A.S. Civico, Via Piazzale Leotta, Palermo and  ., Arnone A; Nuclear Medicine Unit, Azienda Unità Sanitaria Locale IRCCS, via Amendola, Reggio Emilia, Italy., Vultaggio V; Nuclear Medicine Unit, Department of Radiological Sciences,  ., Longo C; Nuclear Medicine Unit, Department of Radiological Sciences,  ., Fiasconaro E; Nuclear Medicine Unit, Department of Radiological Sciences,  ., Mirabile A; Nuclear Medicine Unit, Department of Radiological Sciences,  ., Ricapito R; Nuclear Medicine Unit, Department of Radiological Sciences,  ., Blasi L; Oncology Unit, Department of Surgery, A.R.N.A.S. Civico, Via Piazzale Leotta, Palermo and  ., Arnone G; Nuclear Medicine Unit, Department of Radiological Sciences,  ., Messina C; Oncology Unit, Department of Surgery, A.R.N.A.S. Civico, Via Piazzale Leotta, Palermo and  .
Jazyk: angličtina
Zdroj: Nuclear medicine communications [Nucl Med Commun] 2024 Jul 01; Vol. 45 (7), pp. 622-628. Date of Electronic Publication: 2024 Apr 27.
DOI: 10.1097/MNM.0000000000001850
Abstrakt: Aim: The early detection of prostate cancer (PCa) metastatic disease with PET imaging leads to stage migration and change of disease management. We aimed to assess the impact on clinical management deriving from prostate-specific membrane antigen (PSMA) imaging with a digital PET/CT during the routine application in the staging and restaging process of PCa.
Material and Methods: Eighty consecutive PCa patients underwent 18F-PSMA-1007. Digital PET/CT were retrospectively evaluated and discussed with oncologists to evaluate the impact on clinical management. Performances analysis, correlation among variables also considering semiquantitative parameters have been conducted.
Results: In the whole group of 80 patients at staging (N = 31) and restaging (N = 49), the detection rate of PSMA PET was 85% for all lesions. At staging, the performance analysis resulted in sensitivity 77.6%, specificity 89.5%, negative predictive value (NPV) 77.6%, positive predictive value (PPV) 89.5%, accuracy 85.7%, and area under curve (AUC) 0.87%. The performance of restaging PET in the group of patients with PSA values <1 ng/ml resulted in the following values: sensitivity 66.7%, specificity 92.9%, NPV 85.7%, PPV 81.3%, accuracy 82.6%, and AUC 0.79. Semiquantitative analysis revealed a mean value of SUVmax, metabolic tumor volume, and total lesion PSMA expression with differences in patients with high risk compared to low intermediate. At restaging PET, semiquantitative values of patients with total prostate specific antigen (tPSA) ≤ 1 ng/ml were significantly less than those of the tPSA > 1 ng/ml. A significant impact on clinical management was reported in 46/80 patients (57.5%) based on PSMA PET findings at staging and restaging.
Conclusion: Although PSMA-PET provides optimal performances, its current role in redefining a better staging should be translated in the current clinical scenario about potential improvement in clinical/survival outcomes.
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: